MERIT Study –anti-VEGF monotherapy can provide a meaningful fluid response in a subset of MESI patients 52 Acharya NR, et al. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023 Sep;130(9):914-923. Dexamethasone implant Proportion of eyes with normalization of OCT CST Eyes, % Ranibizumab Methotrexate Dexamethasone implant Ranibizumab Methotrexate Anti-VEGF monotherapy (ranibizumab) can have a meaningful anatomical response in almost half of patients and completely resolve fluid in ~25% of patients Proportion of eyes with a meaningful OCT CST response Eyes with a ≥20% decrease in OCT CST, %